Analysts predict that Dynavax Technologies Co. (NASDAQ:DVAX) will announce ($0.24) earnings per share (EPS) for the current quarter, Zacks reports. Two analysts have made estimates for Dynavax Technologies’ earnings, with estimates ranging from ($0.31) to ($0.21). Dynavax Technologies posted earnings per share of ($0.34) in the same quarter last year, which would indicate a positive year-over-year growth rate of 29.4%. The firm is expected to announce its next earnings report after the market closes on Thursday, February 25th.
On average, analysts expect that Dynavax Technologies will report full year earnings of ($0.84) per share for the current fiscal year, with EPS estimates ranging from ($0.86) to ($0.82). For the next financial year, analysts forecast that the business will report earnings of ($0.17) per share, with EPS estimates ranging from ($0.23) to ($0.08). Zacks’ EPS averages are a mean average based on a survey of sell-side research analysts that that provide coverage for Dynavax Technologies.
A number of research firms have issued reports on DVAX. HC Wainwright boosted their price target on Dynavax Technologies from $14.00 to $15.00 and gave the company a “buy” rating in a research report on Monday, February 1st. William Blair reissued a “buy” rating on shares of Dynavax Technologies in a research report on Friday, December 18th. Finally, Zacks Investment Research raised Dynavax Technologies from a “hold” rating to a “buy” rating and set a $12.00 price target for the company in a research report on Wednesday, February 10th. Five investment analysts have rated the stock with a buy rating, The company has an average rating of “Buy” and a consensus target price of $15.25.
DVAX stock traded down $0.52 during trading on Tuesday, reaching $9.08. 4,068,281 shares of the stock traded hands, compared to its average volume of 7,973,801. The business’s 50 day moving average price is $7.31 and its 200-day moving average price is $5.55. Dynavax Technologies has a 52-week low of $1.80 and a 52-week high of $12.44. The company has a debt-to-equity ratio of 2.59, a current ratio of 4.35 and a quick ratio of 3.47. The firm has a market capitalization of $1.00 billion, a PE ratio of -6.63 and a beta of 1.34.
About Dynavax Technologies
Dynavax Technologies Corporation, a biopharmaceutical company, focuses on leveraging the power of the body's innate and adaptive immune responses through toll-like receptor stimulation. The company markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older.
Featured Article: What is Blockchain?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Dynavax Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dynavax Technologies and related companies with MarketBeat.com's FREE daily email newsletter.